Trevi Therapeutics schedules FDA meeting for chronic cough program By Investing.com
Trevi Therapeutics (NASDAQ: TRVI) has scheduled an End-of-Phase 2 meeting with the FDA in Q1 2026 to discuss its chronic cough program for idiopathic pulmonary fibrosis (IPF) patients, focusing on its investigational therapy Haduvio. The company plans to initiate a Phase 2b trial for refractory chronic cough in H1 2026 and expects to launch its Phase 3 program for nalbuphine ER in the IPF patient population in H1 2026. Despite being pre-revenue, Trevi boasts a strong financial position, with significant stock performance gains and positive analyst outlooks.
How this was made
The 30-second read
Why it matters
Upcoming FDA meeting is a critical milestone that could accelerate development and approval processes, influencing stock valuation.
Market read
The scheduled FDA meeting represents a significant catalyst for Trevi Therapeutics, with potential to influence stock price and investor sentiment.
What to watch
Potential regulatory hurdles or trial setbacks that could negate optimistic outlooks.
Background
Trevi Therapeutics is developing Haduvio for chronic cough associated with IPF, with recent positive analyst outlooks and strong financials despite being pre-revenue.
Ticker impact
High relevance due to upcoming FDA meeting and clinical trial developments.
Potential short-term increase in stock price around FDA meeting; long-term outlook depends on trial outcomes.
The scheduled FDA meeting and planned trial initiations are key catalysts that typically influence biotech stock valuations positively, especially given the company's strong financial position and analyst optimism.
Market effects
Potential positive impact on the life sciences sector, especially respiratory and pulmonary therapeutics.
Primarily affecting US biotech stocks; limited immediate regional impact.
Moderate, as developments pertain to US regulatory processes but could influence global respiratory drug development trends.
Counterpoint
FDA meeting may lead to increased scrutiny or delays, which could negatively impact stock performance.
Key entities
- CompanyTrevi Therapeutics
Biotech company focusing on respiratory and neurological therapies.
- Drug CandidateHaduvio
Investigational therapy for chronic cough in IPF patients.
- Regulatory AgencyFDA
U.S. Food and Drug Administration, overseeing drug approvals.
